Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Suramin in Treating Patients With Refractory or Relapsed Multiple Myeloma or Castleman's Disease
This study has been completed.
Study NCT00002652 Information provided by National Cancer Institute (NCI)
First Received: November 1, 1999 Last Updated: November 16, 2008
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Additional conditions recognized in this trial
Giant Lymph Node Hyperplasia
Multiple Myeloma
Neoplasms
Neoplasms, Plasma Cell
More general conditions related to this trial
Blood Protein Disorders
Cardiovascular Diseases
Hematologic Diseases
Hemorrhagic Disorders
Hemostatic Disorders
Immune System Diseases
Immunoproliferative Disorders
Lymphatic Diseases
Lymphoproliferative Disorders
Neoplasms by Histologic Type
Paraproteinemias
Vascular Diseases
Interventions listed in this trial
suramin
More general drug interventions related to this trial
Anthelmintics
Anti-Infective Agents
Antinematodal Agents
Antineoplastic Agents
Antiparasitic Agents
Antiprotozoal Agents
Pharmacologic Actions
Therapeutic Uses
Trypanocidal Agents
Sponsors listed in this trial
University of Arkansas
National Cancer Institute (NCI)
Back to top of Main Content
